We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals

224 hedge funds and large institutions have $1.4B invested in Supernus Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 74 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

266% more call options, than puts

Call options by funds: $3.33M | Put options by funds: $911K

6% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 34

5% more capital invested

Capital invested by funds: $1.33B → $1.4B (+$65.1M)

3% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 74

0.36% more ownership

Funds ownership: 100.46%100.82% (+0.36%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0% less funds holding

Funds holding: 225224 (-1)

Holders
224
Holders Change
-1
Holders Change %
-0.44%
% of All Funds
3.93%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
36
Increased
76
Reduced
74
Closed
34
Calls
$3.33M
Puts
$911K
Net Calls
+$2.42M
Net Calls Change
-$1M

SUPN Hedge Fund Activity: Q1 2021 in Review

224 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2021, worth a combined $1.4B — up 4.9% from $1.33B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new SUPN positions and 34 closed out — a net gain of 2 holders — while 76 added to existing stakes and 74 trimmed.

The largest buyer was Frontier Capital Management, opening a new position worth an estimated $21.5M. The largest seller was Fuller & Thaler Asset Management, cutting an estimated $27.5M.

  • 224 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2021, down from 225 in Q4 2020.
  • Funds reported $1.4B of Supernus Pharmaceuticals stock for Q1 2021, up 4.9% quarter-over-quarter.
  • 36 funds opened new Supernus Pharmaceuticals positions in Q1 2021 and 34 closed out, a net change of +2 holders.
  • The largest Supernus Pharmaceuticals buyer in Q1 2021 was Frontier Capital Management, an estimated $21.5M added.
  • The largest Supernus Pharmaceuticals seller in Q1 2021 was Fuller & Thaler Asset Management, an estimated $27.5M sold.

Based on aggregated 13F filings for Q1 2021.